Mercer Global Advisors
CHRS icon

Mercer Global Advisors’s Coherus Oncology CHRS Stock Holding History

Mercer Global Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.2K Buy
26,580
+11,663
+78% +$19K ﹤0.01% 3544
2026
Q1 		$25.2K Buy
+14,917
New +$26.5K ﹤0.01% 3177

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Mercer Global Advisors's CHRS Position: Q2 2026 in Review

Mercer Global Advisors increased its Coherus Oncology (CHRS) stake by 78% in Q2 2026, buying an estimated $19K and bringing the position to 26,580 shares worth $37.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3544.

Mercer Global Advisors first reported a position in CHRS in Q1 2026 and has held it in 2 quarters since. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Mercer Global Advisors held 26,580 shares of Coherus Oncology worth $37.2K as of Q2 2026.
  • Mercer Global Advisors bought 11,663 Coherus Oncology shares in Q2 2026, an estimated $19K.
  • Coherus Oncology made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3544 holding.
  • Mercer Global Advisors first reported a position in Coherus Oncology in Q1 2026 and has held it in 2 quarters since.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.